Stinchcombe et al. evaluated T-DM1 in patients with HER2 overexpression.40 No responses were seen in patients with HER2 2+ tumour expression (n = 29), while an objective response rate of 20% was seen for patients with HER2 3+ tumour expression (n = 20). The gene discussed is ERBB2; the disease is neoplasm.